Business
2 Icahn allies win Biogen Idec posts
June 10, 2009
The shares of both biotech companies fall 5% as doubts arise about price and compatibility.
June 24, 2003
Biotechnology firm Biogen Idec Inc. said Friday that it was exploring a possible sale of the company and that billionaire Carl Icahn, who had recently bought company shares, had expressed interest.
Oct. 13, 2007
William Rastetter says it would bring cost savings, broaden the scope of products and take the U.S.-centered company global.
Nov. 12, 2003
The biotech company’s results are hurt by an $833-million write- down on research and development projects.
March 3, 2004
Biogen Idec’s facility in Oceanside, slated to open in 2005, will bring to the area much-wanted manufacturing jobs.
June 20, 2004
The multiple sclerosis drug reduced the relapse rate of patients by 66% in a clinical trial, the companies say.
Nov. 9, 2004
Biogen-Idec of Cambridge, Mass., won Food and Drug Administration approval for its multiple sclerosis drug Tysabri, formerly called Antegren.
Nov. 24, 2004
Biogen Inc. said the Antegren medicine it’s developing with Ireland’s Elan Corp. failed to significantly reduce symptoms of an intestinal disorder in a study.
July 25, 2003
Federal regulators are formally investigating possible securities law violations related to Biogen Idec Inc.’
April 30, 2005